Kyverna Therapeutics (Kyverna Therapeutics) Cash, Cash Equivalents, Marketable Securities : $369.79 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Cash, Cash Equivalents, Marketable Securities?

Kyverna Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($77.27 Mil) to Dec. 2023 ($57.54 Mil) but then increased from Dec. 2023 ($57.54 Mil) to Mar. 2024 ($369.79 Mil).

Kyverna Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($76.07 Mil) to Dec. 2022 ($51.32 Mil) but then increased from Dec. 2022 ($51.32 Mil) to Dec. 2023 ($57.54 Mil).

Kyverna Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Kyverna Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

76.07

51.32

57.54

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			51.32	-	77.27	57.54	369.79

Kyverna Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Kyverna Therapeutics (NAS:KYTX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Kyverna Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024